At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 84 enrolled
Drug / intervention
rasagiline (Pharmacodynamics) +1 moredrug
Likely dose
rasagiline (Pharmacodynamics) 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
In Brief
A Phase 4 clinical trial evaluating rasagiline (Pharmacodynamics) and Placebo for Schizophrenia. Completed, enrolled 84 participants across 5 sites.
Detailed Summary
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration for the treatment of Parkinson's disease. It is used to treat cognitive problems.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJun 2007
Primary CompletionFeb 2012
TodayJul 2026
First PostedJun 27, 2007
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.0 years ago
Interventions
rasagiline (Pharmacodynamics)drug
Rasagiline 1 mg/day for 12 weeks
Placebodrug
Placebo 1 tablet each day